Maitane Echeverría Urroz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maitane Echeverría Urroz has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ana Isabel López Delgado
Laboratorio Bioquímica , 16650 Hospital Universitario Donostia , Donostia , España
2 shared publicationsDavid Álvarez Nistal
Laboratorio Bioquímica , 16650 Hospital Universitario Donostia , Donostia , España
2 shared publicationsRaquel Oliveros Conejero
Laboratorio Bioquímica , 16650 Hospital Universitario Donostia , Donostia , España
2 shared publications- Adolfo Garrido
Donostialdea Integrated Health Organisation, Clinical Biochemistry Department, Osakidetza Basque Health Service, 20014 Donostia, Spain
1 shared publication - Ainara Estanga
Center for Research and Memory Clinic, CITA-Alzhéimer Foundation, 20009 Donostia-San Sebastián, Spain
1 shared publication - Ainhoa Fiz
Atzegi, 20004 Donostia, Spain
1 shared publication
Latest Publications
- Open Access
- 31 March 2025
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 6 (2) , 217-220
Diagnóstico de hemoglobinopatías en el laboratorio clínico: hallazgo de una hemoglobina hofu oculta en HPLC
Resumen: Objetivos: Las hemoglobinopatías son trastornos que afectan a la estructura, función y/o producción de hemoglobina. Obedecen a mutaciones o deleciones en los genes codificantes para la síntesis de globina. La presentación clínica es muy variable, desde formas asintomáticas hasta anemia grave. Para su diagnóstico es necesario el estudio mediante pruebas de laboratorio. Caso clínico: En este artículo, se presenta el caso de una paciente que consulta por astenia. Debido a antecedentes familiares de hemoglobinopatía, se realiza estudio de eritropatías. La cromatografía líquida de alta resolución (HPLC) muestra un perfil normal de distribución de hemoglobinas. El estudio mediante electroforesis capilar de zona en medio alcalino, en cambio, pone en evidencia un pico de migración rápida sin identificar. Tras estudio genético, se detecta una mutación en el gen HBB causante de hemoglobinopatía Hofu. Conclusiones: a hemoglobina variante Hofu es una hemoglobina levemente inestable. En formas heterocigotas es habitualmente asintomática, pero en combinación con otras alteraciones puede causar anemia. Característicamente, el tiempo de retención de la Hb Hofu en HPLC es muy cercano al de la Hb A(0) y a menudo eluyen juntas. Por tanto, su detección puede quedar enmascarada y conllevar a errores en la interpretación del estudio.
- 31 March 2025
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 6 (2) , 217-220
Open AccessDiagnóstico de hemoglobinopatías en el laboratorio clínico: hallazgo de una hemoglobina hofu oculta en HPLC
Resumen: Objetivos: Las hemoglobinopatías son trastornos que afectan a la estructura, función y/o producción de hemoglobina. Obedecen a mutaciones o deleciones en los genes codificantes para la síntesis de globina. La presentación clínica es muy variable, desde formas asintomáticas hasta anemia grave. Para su diagnóstico es necesario el estudio mediante pruebas de laboratorio. Caso clínico: En este artículo, se presenta el caso de una paciente que consulta por astenia. Debido a antecedentes familiares de hemoglobinopatía, se realiza estudio de eritropatías. La cromatografía líquida de alta resolución (HPLC) muestra un perfil normal de distribución de hemoglobinas. El estudio mediante electroforesis capilar de zona en medio alcalino, en cambio, pone en evidencia un pico de migración rápida sin identificar. Tras estudio genético, se detecta una mutación en el gen HBB causante de hemoglobinopatía Hofu. Conclusiones: a hemoglobina variante Hofu es una hemoglobina levemente inestable. En formas heterocigotas es habitualmente asintomática, pero en combinación con otras alteraciones puede causar anemia. Característicamente, el tiempo de retención de la Hb Hofu en HPLC es muy cercano al de la Hb A(0) y a menudo eluyen juntas. Por tanto, su detección puede quedar enmascarada y conllevar a errores en la interpretación del estudio.
- Open Access
- 23 January 2025
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 6 (2) , 213-216
Diagnosis of hemogobinopathies in the clinical laboratory: an occult Hofu hemoglobin on HPLC
Objectives: Hemoglobinopathies are disorders affecting the structure, function and/or production of hemoglobin. These conditions are caused by mutations in the genes encoding globin synthesis. The highly variable clinical manifestations of hemoglobin disorders range from asymptomatic forms to severe anemia. Laboratory tests are crucial for diagnosis. Case presentation: We report the case of a patient who presented with asthenia. Since the patient had a family history of hemoglobonipathies, screening for erythropathies was performed. High-resolution liquid chromatography (HPLC) showed a normal distribution of hemoglobin levels. In contrast, capillary zone electrophoresis at alkaline pH demonstrated an unidentified rapid migration peak. Genetic testing revealed a mutation in the HBB gene causing Hofu hemoglobin disease. Conclusions: The hemoglobin variant Hofu is slightly unstable. While heterozygous carriers most frequently remain asymptomatic, they may develop anemia in the presence of other concomitant disorders. Distinctively, the retention time of Hb Hofu on HPLC is very close to that of HbA (0) and they often elute together. Therefore, Hb Hofu may remain masked, thereby leading to the misinterpretation of test results.
- 23 January 2025
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 6 (2) , 213-216
Open AccessDiagnosis of hemogobinopathies in the clinical laboratory: an occult Hofu hemoglobin on HPLC
Objectives: Hemoglobinopathies are disorders affecting the structure, function and/or production of hemoglobin. These conditions are caused by mutations in the genes encoding globin synthesis. The highly variable clinical manifestations of hemoglobin disorders range from asymptomatic forms to severe anemia. Laboratory tests are crucial for diagnosis. Case presentation: We report the case of a patient who presented with asthenia. Since the patient had a family history of hemoglobonipathies, screening for erythropathies was performed. High-resolution liquid chromatography (HPLC) showed a normal distribution of hemoglobin levels. In contrast, capillary zone electrophoresis at alkaline pH demonstrated an unidentified rapid migration peak. Genetic testing revealed a mutation in the HBB gene causing Hofu hemoglobin disease. Conclusions: The hemoglobin variant Hofu is slightly unstable. While heterozygous carriers most frequently remain asymptomatic, they may develop anemia in the presence of other concomitant disorders. Distinctively, the retention time of Hb Hofu on HPLC is very close to that of HbA (0) and they often elute together. Therefore, Hb Hofu may remain masked, thereby leading to the misinterpretation of test results.
- Open Access
- 17 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1139
Down Syndrome—Basque Alzheimer Initiative (DS-BAI): Clinic-Biological Cohort
Background: Down syndrome (DS) is the most common genetically determined intellectual disability. In recent decades, it has experienced an exponential increase in life expectancy, leading to a rise in age-related diseases, including Alzheimer’s disease (AD). Specific health plans for the comprehensive care of the DS community are an unmet need, which is crucial for the early and accurate diagnosis of main medical comorbidities. We present the protocol of a newly created clinical and research cohort and its feasibility in real life. Methods: The Down Syndrome—Basque Alzheimer Initiative (DS-BAI) is a population-based, inclusive, multidisciplinary initiative for the clinical-assistance and clinical-biological research approach to aging in DS led by the CITA-Alzheimer Foundation (Donostia, Basque Country). It aims to achieve the following: (1) provide comprehensive care for adults with DS, (2) optimize access to rigorous and quality training for socio-family and healthcare references, and (3) create a valuable multimodal clinical-biological research platform. Results: During the first year, 114 adults with DS joined the initiative, with 36% of them showing symptoms indicative of AD. Furthermore, adherence to training programs for healthcare professionals and families has been high, and the willingness to collaborate in basic and translational research has been encouraging. Conclusion: Specific health plans for DS and conducting clinical and translational research on the challenges of aging, including AD, are necessary and feasible.
- 17 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1139
Open AccessDown Syndrome—Basque Alzheimer Initiative (DS-BAI): Clinic-Biological Cohort
Background: Down syndrome (DS) is the most common genetically determined intellectual disability. In recent decades, it has experienced an exponential increase in life expectancy, leading to a rise in age-related diseases, including Alzheimer’s disease (AD). Specific health plans for the comprehensive care of the DS community are an unmet need, which is crucial for the early and accurate diagnosis of main medical comorbidities. We present the protocol of a newly created clinical and research cohort and its feasibility in real life. Methods: The Down Syndrome—Basque Alzheimer Initiative (DS-BAI) is a population-based, inclusive, multidisciplinary initiative for the clinical-assistance and clinical-biological research approach to aging in DS led by the CITA-Alzheimer Foundation (Donostia, Basque Country). It aims to achieve the following: (1) provide comprehensive care for adults with DS, (2) optimize access to rigorous and quality training for socio-family and healthcare references, and (3) create a valuable multimodal clinical-biological research platform. Results: During the first year, 114 adults with DS joined the initiative, with 36% of them showing symptoms indicative of AD. Furthermore, adherence to training programs for healthcare professionals and families has been high, and the willingness to collaborate in basic and translational research has been encouraging. Conclusion: Specific health plans for DS and conducting clinical and translational research on the challenges of aging, including AD, are necessary and feasible.